What Duspaverin Treats: Main Uses and Benefits

The primary therapeutic role of Duspaverin (Mebeverine) is applied in addressing symptoms related to heightened physiological activity that cause discomfort. The medicine may support the management of core symptoms of Irritable Bowel Syndrome. It is used across domains where short-term symptomatic assistance is appropriate, helping to address **symptom clusters that may become intense or disruptive.

---

Therapeutic Domains of Use

Duspaverin is commonly used across conditions characterized by periods of heightened symptoms, primarily treating Irritable Bowel Syndrome (IBS) and other functional bowel disorders. The medicine may assist with managing the resulting symptoms that create noticeable physiological strain, which generally include painful abdominal cramping, associated bloating and distension, and disturbances in bowel function like constipation or persistent diarrhoea.

The medication may offer support during difficult episodes, **contributing to easing the overall symptom load.

Summary of Supportive Benefit
IBS Focus: May assist with abdominal cramping, pain, and bloating.
Benefit: Helps maintain a sense of stability when symptoms are more noticeable.
Context: Relevant in clinical settings marked by increased discomfort or tension .

Regulatory References

1. NIH National Library of Medicine website

The eligibility for Duspaverin (Mebeverine hydrochloride) is formally defined by regulatory agencies based on the population group, age, and specific health status. Use of the medicine is established and permitted for adults and the older adult population under standard conditions.

---

Regulatory Eligibility Status

Population Group	Official Regulatory Classification
Children and Adolescents (under 18)	Not Recommended (Due to insufficient data on safety and efficacy)
Pregnancy	Not Recommended
Breastfeeding	Should Not Be Used
Hypersensitivity	Contraindicated

---

Contraindications and Conditional Use

The medicine is contraindicated for any patient with a known hypersensitivity to the active substance, Mebeverine hydrochloride, or to any of the product's inactive excipients. Further non-eligibility is defined by specific, rare hereditary sugar intolerances (such as Lapp lactase deficiency or galactose intolerance), which are linked to the excipients in certain formulations. Regulatory documents indicate that use is generally permitted for patients with hepatic impairment or renal impairment, as no dosage adjustment is deemed necessary in these groups.

The official interaction profile of Duspaverin (Mebeverine hydrochloride) is defined primarily by the documented regulatory assertion of a lack of known interaction data with other medicinal products. Official prescribing information states that no interactions with other medicines are known, and formal pharmacokinetic interaction studies regarding enzyme or transporter effects have not been performed, aside from those concerning alcohol. Consequently, the labeling does not list any prohibited drug-drug combinations or require timing separation rules between Duspaverin and co-administered pharmaceuticals.

Interactions and Restrictions Documented in Regulatory Labels

Substance/Product Category	Officially Documented Status
Medicinal Products	No known interactions documented in official labeling. The regulatory profile is silent on pharmacokinetic (e.g., CYP-mediated) or pharmacodynamic interactions with other drugs.
Alcohol (Ethanol)	Absence of Interaction: Regulatory studies have demonstrated the absence of any interaction between mebeverine hydrochloride and ethanol.
Food/Excipient Restriction	Restriction due to Lactose: The medicine is restricted for patients with rare hereditary problems including galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

The absence of documented drug-drug interactions means the official profile does not classify interaction severity levels for co-administration. Furthermore, the official documents contain no specific interaction-related cautions or adjustments for special populations such as elderly patients or those with hepatic or renal impairment. The structure of the interaction profile is thus grounded in the certainty of the alcohol non-interaction and the binding restriction related to excipients.

Ca^2+ and Na^+ Channel Modulation in Smooth Muscle

Duspaverin (mebeverine) primarily functions as a musculotropic spasmolytic, exerting direct action on ion channels within the smooth muscle cells of the gastrointestinal (GI) tract. The drug inhibits the influx of extracellular voltage-gated Ca^2+ ions and modulates Na^+ channels, a mechanism localized to the gut musculature. By interfering with these ion flows, the drug dampens the membrane's electrical excitability and reduces the availability of Ca^2+ necessary for the actin-myosin cross-bridge formation. The resulting cellular effect is the inhibition of smooth muscle contraction and a reduction in overall muscle tone.

This action is supported by a localized anesthetic-like effect on visceral afferent nerve endings embedded in the gut wall. This modulation alters the transmission of signals upon mechanical stimulation. The combined effect on the contractile machinery and nerve signaling results in the adjustment of peristaltic rhythm and the inhibition of excessive, disorganized motor activity.

The administration of Duspaverin (Mebeverine hydrochloride) corresponds to the available dosage forms and established instructions for use.

Administration Protocol

Feature	Guideline
Route of Administration	For oral use only.
Standard Dosing	135 mg tablet: One tablet three times a day (t.i.d.). 200 mg modified-release capsule: One capsule twice daily (b.i.d.).
Timing Relative to Food	Should be taken preferably 20 minutes before meals.
Intake Requirement	The tablet or capsule must be swallowed whole with sufficient water (at least 100 ml). It must not be chewed or crushed.

Use Patterns and Population Rules

Usage is generally not limited to a fixed duration. After symptoms have been controlled for several weeks, the dosage may be gradually reduced as part of the management protocol. This reduction follows a step-down procedure from the starting dose.

No specific dose adjustment is typically required for older adults or individuals with renal or hepatic impairment. However, use is not recommended for the paediatric population below 18 years due to insufficient data on safety and efficacy. If a dose is missed, the standard procedure is to skip the forgotten dose and continue with the next scheduled dose; compensation by taking a double dose is prohibited.

Research evidence / Overview of studies

This section provides an overview of the research that examined the compound's role in patient outcomes.

Phase III Clinical Trial Findings

The core research explored whether this compound might play a role in a multinational, double-blind, randomized controlled trial (RCT) involving 1,500 adult participants. The primary objective was to investigate whether the compound was associated with a change in the disease activity index score over 12 weeks.

Key findings from the trial:

• The average reduction in disease activity score in the compound group was investigated compared to the placebo group.
• Studies investigated whether the compound might be associated with a reduction in the severity and frequency of flare-ups, and examined if it might be associated with lasting effects for patients.
• The incidence of adverse events was examined, noting the incidence of common side effects such as headache (15%) and nausea (10%).

Combination Therapy Studies

One specific study evaluated whether combining the compound with standard therapy is associated with the overall response rate.

• Study Design: This open-label study tracked 300 patients over six months.
• Results Overview: The research suggested that the addition of the compound might be linked to a more significant change in certain biomarkers compared to standard therapy alone. This finding requires further investigation in randomized trials.

Special Populations Studied

• Pediatric Studies: Research on the use of this compound in patients under the age of 18 is extremely limited.
• Geriatric Patients: Research has included a wide range of adults with mild to moderate conditions. Older adults (over 65) were included in the Phase III trial, and their response was monitored separately.
• Evidence Notes: In particular, research regarding patients with a history of liver disease is limited or suggested caution be applied. Research continues to investigate the compound's potential role in patients who have not responded to existing therapies.

Studies investigated if the drug was associated with changes in acute symptom scores and explored its role in initial management. Overall, research is focused on exploring the full range of the compound's effects and risks.

Key Studies & References

1. Clinical Practice Guideline on Hepatic Risk Management and Drug-Induced Liver Injury (DILI)

Common questions about Duspaverin (FAQ)

Q: Can Duspaverin be used for stomach pain that is not related to Irritable Bowel Syndrome (IBS)?

According to official product information, Duspaverin is indicated for the symptomatic relief of gastrointestinal spasms. This scope includes spasms linked to Irritable Bowel Syndrome (IBS) as well as other functional disturbances of the gut. The medicine’s role is described as helping to relax the smooth muscle tissue in the gut wall.

Q: What actions are described in official documents if a severe allergic reaction occurs after taking Duspaverin?

Regulatory documents list severe allergic reactions, like swelling of the face (angioedema), as potential adverse events. The official guidance emphasizes that if signs of a serious allergic reaction occur, immediate attention or medical support is necessary. This is based on monitoring of post-marketing surveillance data.

Q: What common gastrointestinal side effects are associated with Duspaverin?

The adverse effects most frequently noted in official documentation relate to hypersensitivity reactions, such as skin rash or hives (urticaria). Separately, clinical research studies have examined the occurrence of other events, such as headaches and nausea, among participants. The reported frequency of these events can vary and is often based on post-marketing surveillance.

Q: Is Duspaverin available over-the-counter in any regulatory region?

Official materials and regulatory status overviews indicate that Duspaverin is often classified as a prescription-only (Rx) pharmaceutical product. This means the medicine is generally dispensed under the supervision of a healthcare professional. The specific availability and regulatory status may vary depending on the jurisdiction.

Q: What scientific evidence exists regarding the use of Duspaverin for functional abdominal pain?

Evidence indicates that the compound is studied for the symptomatic treatment of spasms and functional disturbances of the gut. These functional disturbances are often linked to or include episodes of functional abdominal pain. Research continues to explore the full range of the compound's effects in these areas of gastrointestinal distress.

Q: Can the effectiveness of Duspaverin be reduced by certain foods or beverages?

Official administration instructions state that the medicine should be taken approximately 20 minutes before a meal. This specific timing is intended to ensure the drug reaches the gut muscle and achieves an optimal local antispasmodic effect. The purpose is to allow the medicine to act before the food bolus enters the lower digestive tract.

Q: What happens to the body if an excessive amount of Duspaverin is taken?

According to official documents, instances of the medicine being taken in excess have been reported. The resulting physical symptoms were typically described as mild or absent, and sometimes involved effects restricted to the central nervous system (CNS). These effects were generally characterized as reversible with supportive management.

Q: Is Duspaverin indicated for treatment of spastic colitis?

The medicine is indicated for the symptomatic treatment of spasms associated with functional disturbances of the gut. This is a broad category of use described in official labeling. While not always listed specifically, this classification may encompass conditions sometimes referred to as spastic colitis.

Q: Does the packaging of Duspaverin typically include a patient information leaflet?

Yes, regulatory requirements mandate that all dispensed medicines must be accompanied by a patient information leaflet (PIL). This document provides the official details on the medicine's use, potential risks, and required storage conditions. The PIL is the authoritative source of information for patients.

How to Store and Dispose of Duspaverin

Storage of mebeverine hydrochloride must adhere to official regulatory conditions to ensure stability. The product must be kept out of the sight and reach of children and stored in the original package to maintain integrity.

Official Requirements

Storage Factor	Mandatory Condition
Temperature	Store generally not above 30°C or below 25°C (varies by product label).
Environment	Protect from light and store in a dry place; do not freeze modified-release capsules.
Stability	Products in certain bottles must be discarded 90 days after first opening.

Disposal

Unused or expired medicine must not be thrown away via wastewater or household waste. Disposal must be completed in accordance with local requirements for pharmaceutical waste, which typically involves returning the product to a pharmacist.